Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

cus on and commitment to patient communities."

Takeda submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in June, 2013, as well as a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in March, 2013, seeking approval for vedolizumab for the treatment of adults with moderately to severely active CD and UC.

CD and UC are chronic diseases of the digestive tract. CD can involve all areas of the digestive tract, while UC typically affects the colon and rectum. CD and UC can be both painful and debilitating and patients may have bleeding, diarrhea, fatigue, weight loss and anemia, among other symptoms. Both diseases involve excess inflammation in the gut tissue that occurs when white blood cells infiltrate the gastrointestinal tract and may lead to serious complications. 

"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis"
The publication, titled "Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis," discusses findings from GEMINI I, a Phase 3, randomized, double-blind, placebo-controlled induction and maintenance study designed to assess the efficacy and safety of vedolizumab on clinical response and remission in patients with moderately to severely active UC, in whom one prior therapy had failed. In the induction phase, the primary endpoint was improvement in clinical response at six weeks. Secondary endpoints were to determine the effect of vedolizumab induction treatment on clinical remission and mucosal healing at six weeks. The intent-to-treat (ITT) population comprised 374 patients, with an additional 521 patients receiving open-label vedolizumab. Of the 374, 225 received vedolizumab 300 mg IV and 149 received placebo on days 1 and 15. Approximately 40 percent of the ITT population had prior anti-TNF failure. At week six, 47.1 percent of patients receiving vedolizumab achieved clinical response compared to 2
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ – Small Cap IR issues report. Recently, Arrayit ... Arrayit blood card technology to Vivos, Global Genome Vault, ... offers an impervious, impenetrable and permanent DNA storage vault, ... on Earth, a safe and secure nuclear blast-proof, underground ... the rapid collection, separation, drying and storage of human ...
(Date:6/30/2015)... , June 30, 2015  Egalet Corporation ... integrated specialty pharmaceutical company focused on developing, ... announced top-line results from a Category 3 ... an abuse-deterrent, extended-release, oral oxycodone product candidate ... of pain severe enough to require daily, ...
(Date:6/30/2015)... 2015 PharmaVentures is pleased to ... Technologies Oy (CMT) on its divestment of certain assets ... CMTs world leading capabilities in cellular imaging and analysis. ... series of successful global deals in the life science ... Fintan Walton , CEO, PharmaVentures, commented: "PharmaVentures is delighted ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... ... is a reliable source for last minute tickets for The Rolling Stones at Carter ... America in conjunction with their 2015 “Zip Code Tour.” , The Stones have been rocking ... twenties. Some of the most beloved songs that this iconic group has performed over ...
(Date:6/30/2015)... ... , ... According to research by European archeologists that was recently discussed in ... hundred thousand years ago likely knew that eating a balanced diet and limiting smoke ... dental plaque, researchers were able to find evidence of plant fibers, in addition to ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... position as one of Medicare’s top-rated care centers in the country. To spread ... highlighting patient satisfaction and proving its facility is, indeed, worthy of five stars. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Trenton Health Team has been ... Medicaid Accountable Care Organizations (ACO) in the State, serving the greater Trenton community. ... Trenton Health Team ACO draws on the collaborative structure of THT, bringing together the ...
Breaking Medicine News(10 mins):Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3
... epidemic has entered a disturbing new phase, with a study ... the sharp rise in the number of cases. , A ... South Wales (UNSW), believe this emerging new genotype (called ... evading the protective effects of the current acellular vaccine (ACV), ...
... Arabic have more challenges reading in Arabic than native Hebrew ... two halves of the brain divide the labor differently when ... English. That is the result of a new study conducted ... the Edmond J. Safra Brain Research Center for the Study ...
... of anesthesia providers to monitor sedation during screening colonoscopies ... 2003 to 2009 in the United States, with most ... need this service, according to a new RAND Corporation ... $1.1 billion spent annually on anesthesia services for GI-related ...
... Austria: New research has shown for the first time that ... oestrogen receptor positive breast cancer to become pregnant, despite doctors, ... the body and cause the cancer to return. In ... eighth European Breast Cancer Conference (EBCC-8) in Vienna, suggest that ...
... TUESDAY, March 20 (HealthDay News) -- Calculating the ... and right arms might help predict a patient,s odds ... Researchers found that people with high blood pressure ... at higher risk of cardiovascular death over 10 years. ...
... a consortium of investigators from 13 countries led the University ... Catholic University of Leuven, Belgium in Europe, found that nurses ... of leaving also had patients who were more satisfied with ... study was released today in the current issue of the ...
Cached Medicine News:Health News:Sharp rise in cases of new strain of whooping cough 2Health News:Sharp rise in cases of new strain of whooping cough 3Health News:Brain's involvement in processing depends on language's graphic symbols 2Health News:Brain's involvement in processing depends on language's graphic symbols 3Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Pregnancy is safe for women with estrogen receptor positive breast cancer 2Health News:Pregnancy is safe for women with estrogen receptor positive breast cancer 3Health News:Pregnancy is safe for women with estrogen receptor positive breast cancer 4Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:International research finds quality and safety problems in hospitals throughout 13 countries 2
Telescopic Diamond-Dissectors for delicate sharp tissue preparation. Total/working lengths 220/240 mm with protective sleeve....
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Cobb Spinal Curettes, tip size 13.00 mm, length 11" (279 mm)....
Karlin XL Magnum Ring Curettes, extra long (XL) curettes, black handles, lightweight. Length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Medicine Products: